IGF-1 drug approved by FDA

by Medindia Content Team on  November 26, 2005 at 6:37 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

IGF-1 drug approved by FDA
Insulin like-Growth Factor (IGF-1) is required for both cartilage and bone growth in children's and the secretion of IGF is mediated by the pituitary gland. Deficiency of IGF-1 results in impaired growth and is associated with metabolic abnormalities including insulin resistance, increased adiposity and delayed wound healing. IGF-1 drugs helps in production of IGF-1 in children's with deficiency in production of IGF-1.

The pharmaceutical company Tercica drug, Increlex against IGF-1 deficiency has been approved by the U.S. FDA to produce recombinant human IGF-1 as a long term treatment for children with severe primary IGF-1 deficiency. The results of the new recombinant drug has to be monitored as earlier IGF-1 drugs produced by pharmaceuticals like Genetech for treatment of diabetes and Cephalon pharmacies IGF-1 drug against Amyotrophic lateral sclerosis had been withdrawn due to its side effects in patients.


Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive